Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25467291 | 0.94 | SLC22A1 (0.36) | USP2EPHX1CYP2D6SLC22A1CHRM2 | |
| SCHEMBL6625522 | 0.86 | — | — | |
| SCHEMBL19045071 | 0.86 | — | — | |
| SCHEMBL19063296 | 0.83 | EPHX1 (0.34) | EPHX1EHMT2 | |
| SCHEMBL23466099 | 0.80 | SLC22A1 (0.34) | USP2CYP2D6SLC22A1CHRM2ACHE | |
| SCHEMBL14413879 | 0.80 | USP2 (0.33) | USP2OPRM1 | |
| SCHEMBL22421781 | 0.78 | EPHX1 (0.34) | EPHX1VNN1 | |
| SCHEMBL22663697 | 0.77 | USP2 (0.32) | USP2 | |
| SCHEMBL23774546 | 0.76 | KMT2A (0.42) | USP2CYP2D6CYP2C9TSHRHSD17B10 | |
| SCHEMBL26790736 | 0.76 | USP2 (0.33) | USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113933432-B | High-sensitivity and high-precision analysis method suitable for detecting alkaloid in tobacco leaves | 中国烟草总公司郑州烟草研究院 | 2023-08-25 | — | — | CN | claimed |
| US-20260001838-A1 | NANOMATERIALS | GUIDE THERAPEUTICS LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12435035-B2 | Nanomaterials | GUIDE THERAPEUTICS, LLC (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4596551-A1 | COMPOUNDS WITH ANTI-KRAS MUTANT TUMOR ACTIVITY | Trasveda Ltd. (KY) | 2025-08-06 | — | — | EP | disclosed |
| CN-119684140-A | Nanomaterial for the preparation of a nanoparticle | 盖德治疗有限责任公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2024259169-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| CN-115175894-B | Nanomaterial for the preparation of a nanoparticle | 盖德治疗有限责任公司 | 2024-09-06 | — | — | CN | disclosed |
| WO-2024067714-A1 | COMPOUNDS WITH ANTI-KRAS MUTANT TUMOR ACTIVITY | 泰励生物科技（上海）有限公司 | 2024-04-04 | — | — | WO | disclosed |
| CN-117800975-A | Compounds with anti-KRAS mutant tumor activity | 泰励生物科技（上海）有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-113933432-B | High-sensitivity and high-precision analysis method suitable for detecting alkaloid in tobacco leaves | 中国烟草总公司郑州烟草研究院 | 2023-08-25 | — | — | CN | disclosed |
| US-7932259-B2 | Pyrrolo[2,3-d]pyrimidine derivatives substituted with a cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7723331-B2 | Thienopyrimidine compounds and uses thereof | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| EP-2121703-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| CN-101528751-A | Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as MCH Rl antagonists | ASTRAZENECA AB (SE) | 2009-09-09 | — | — | CN | disclosed |
| US-20080287397-A1 | Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group | TASHO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-20 | — | — | US | disclosed |
| US-20080287397-A1 | Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group | TASHO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-20 | — | — | US | disclosed |
| EP-1987827-A1 | NOVEL PHARMACEUTICAL | Takeda Pharmaceutical Company Limited (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-20080051405-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| WO-2008020799-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
| EP-1787992-A1 | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287397-A1 | Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group | HRH2, HRH4, CRHR1 | USP2 3450/4885EPHX1 884/4885VNN1 3473/4885 |
| US-20080051405-A1 | Therapeutic Agents | GPR119, HTT, IAPP | USP2 4308/4885EPHX1 1031/4885VNN1 3322/4885 |
| US-20260001838-A1 | NANOMATERIALS | SLC10A1, NPC1L1, FABP1 | USP2 3993/4885EPHX1 1462/4885VNN1 2649/4885 |
| US-12435035-B2 | Nanomaterials | NPC1, NPC1L1, FABP1 | USP2 4124/4885EPHX1 1514/4885VNN1 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.